Aptevo Therapeutics logo
Aptevo Therapeutics
APVO | NASDAQ
Chart Builder DCF Calculator
$0.55
-$0.04 (-7.42%)
At close: Nov 16, 2026, 4:00 PM ET
$0.55
$0.00 (-0.47%)
After-hours: Nov 16, 2026, 5:14 PM ET

Aptevo Therapeutics Company Profile

Company profile explained

Company Profile

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

Key Executives

Name Position
Jeffrey G. Lamothe President, Chief Executive Officer & Director
Daphne L. Taylor Senior Vice President & Chief Financial Officer
Dirk Huebner Senior Vice President & Chief Medical Officer
Marvin L. White Executive Chair
Mary J. Janatpour Senior VP & Chief Scientific Officer
Miriam Weber Miller Vice President of Investor Relations & Corporate Communications
SoYoung Kwon Corporate Secretary, Senior Vice President, General Counsel, Business Development & Corporate Affairs

Latest SEC Filings

Date Type Title
Oct 30, 2026 424B5 Filing
Oct 26, 2026 8-K Current Report
Oct 23, 2026 8-K Current Report
Oct 14, 2026 8-K Current Report
Sep 25, 2026 S-8 Filing
Sep 24, 2026 8-K Current Report
Sep 23, 2026 8-K Current Report
Sep 03, 2026 424B4 Filing
Sep 03, 2026 8-K Current Report
Sep 02, 2026 EFFECT Filing
View All SEC Filings ➞
Aptevo Therapeutics
Aptevo Therapeutics logo
Country United States
IPO Date Jul 20, 2016
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Jeffrey G. Lamothe

Contact Details

2401 4th Avenue Seattle, Washington 98121 United States

Stock Details

Ticker Symbol APVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001671584
CUSIP Number 03835L702
ISIN Number US03835L7029
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.